It is well recognised that perinatal mood disorders are common conditions affecting
pregnancy and the postnatal period, and are associated with significant maternal, fetal and
infant morbidity and mortality.1 Inequality in maternal morbidity and mortality is recognised
across a number of socioeconomic in...
This guideline covers recognising, assessing and treating mental health problems in women who are
planning to have a baby, are pregnant, or have had a baby or been pregnant in the past year. It
covers depression, anxiety disorders, eating disorders, drug- and alcohol-use disorders and severe
mental illne...
Preventable physical health conditions lead to premature mortality in people with severe mental disorders, reducing their life span by 10-20 years. The majority of these premature deaths are due to physical health conditions. The physical health of people with severe mental disorders is commonly overlook...
Objetivos: El objetivo principal de esta Guía es recoger recomendaciones concretas basadas en los resultados de la literatura científica para tratar a pacientes con un trastorno mental grave y un consumo de sustancias atendidos en centros de tratamiento hospitalarios y ambulatorios. Incluye: 1) Recomen...
Transtornos Mentais/tratamento farmacológico,
Transtornos Relacionados ao Uso de Substâncias/tratamento farmacológico,
Terapia Psicanalítica,
Antidepressivos/uso terapêutico,
Antipsicóticos/uso terapêutico,
Clozapina/uso terapêutico,
Agonistas de Dopamina/uso terapêutico,
Naltrexona/uso terapêutico,
Bupropiona/uso terapêutico,
Vareniclina/uso terapêutico,
Inibidores Seletivos de Recaptação de Serotonina/uso terapêutico,
Desipramina/uso terapêutico,
Dissulfiram/uso terapêutico,
Buspirona/uso terapêutico
This guideline covers how to improve services for people aged 14 and above who have been diagnosed as having coexisting severe mental illness and substance misuse. The aim is to provide a range of coordinated services that address people’s wider health and social care needs, as well as other issues suc...
In 2015 WHO updated the mhGAP guidelines, first issued in 2009, for the management of mental, neurological and substance use (MNS) disorders. In order to reduce the gap and to enhance the capacity of Member States to respond to the growing challenge, the World Health Organization (WHO) developed the Ment...
This guideline covers recognising, assessing and treating mental health problems in women who are planning to have a baby, are pregnant, or have had a baby or been pregnant in the past year. It covers depression, anxiety disorders, eating disorders, drug- and alcohol-use disorders and severe mental illne...
This guideline covers care for people aged 18 and over with common mental health problems, with a focus on primary care. It aims to improve access to services for adults and how mental health problems are identified and assessed, and makes recommendations on local care pathways. Management of specific me...
Mental disorders are estimated to account for 12% of the global burden of disease, but only a minority of persons affected receive basic treatment. The present manual attempts to provide simple, adequate and evidence-based information to health care professionals especially in low- and middle-income coun...
mhGAP is WHO’s action plan to scale up services for mental, neurological and substance use disorders for countries especially with low and lower middle incomes. The priority conditions addressed by mhGAP are: depression, schizophrenia and other psychotic disorders, suicide, epilepsy, dementia, disorder...
